The AMNOG is considered by many to be a trademark of Germany as a pharmaceutical location and has so far secured its pioneering position in Europe when it comes to patient access to innovative medicines. But is the AMNOG system also fit for medical progress with increasingly targeted therapies? What course needs to be set when the European HTA starts soon? With its “AMNOG 2025” concept, vfa wants to address the current challenges.

Join the discussion about the future of AMNOG and look forward to a constructive discourse between representatives from self-administration (doctors, hospitals, health insurance companies and patient representatives), specialist societies/science and research-based pharmaceutical companies. Using the tried-and-tested fishbowl discussion format, we alternate perspectives so that you also have the opportunity to actively participate.

This round of discussions will take place during the lunch break of the Handelsblatt annual conference HEALTH 2023 and is therefore a suitable addition to the conference program, which this year focuses on the highly relevant topic of “care”.

MODERATION